Main Sector
Biotechnology - Therapeutics and Diagnostics
Subsectors
Small molecules
Immunotherapy
Indications
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Digestive system / gastroenterology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Products
In development: 4
Description
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
